ASTM International established a subcommittee on September 14, 2026, to develop space manufacturing standards for biotechnology, pharmaceuticals, and advanced manufacturing payloads. The U.S. Office of Space Commerce announced the group’s formation on October 13. Designated F47.06, the group will address how research materials and products are prepared, handled, processed, documented, and evaluated across a space mission.
The initiative addresses a practical requirement shared by laboratories and manufacturers: results must be understandable beyond the team that produced them. A returned sample has greater research and commercial usefulness when its identity, handling history, operating conditions, and analytical methods are documented. Common practices could help customers compare work performed by different payload developers and flight providers.
The executive committee approved the subgroup during ASTM’s commercial spaceflight meetings in Washington, hosted by the Federal Aviation Administration. Olivia Gamez Holzhaus of Rhodium Scientific will chair it. Founding participants include representatives associated with the Office of Space Commerce, the National Institute of Standards and Technology, the Biomedical Advanced Research and Development Authority, the Food and Drug Administration, Rhodium Scientific, and Vela Scientific.
The announced scope covers crewed and uncrewed payloads on the International Space Station, commercial orbital platforms, and suborbital systems. It includes controls and analogs, flight materials, preflight preparation, operations in orbit, and postflight evaluation and processing. This broad scope recognizes that the condition of a product can depend on events before launch and after recovery, as well as the process performed in space.
Chain of custody is one stated priority. In practical terms, it records which material moved between organizations, who handled it, and how its identity was maintained. For a flight experiment, that record connects the material prepared in a laboratory with the specimen recovered and tested later. It helps establish that an analytical result belongs to the intended sample and that transfers did not create an undocumented gap.
Environmental conditions and containment are also priorities. Temperature history, exposure conditions, and procedures for keeping materials separated can affect how results are interpreted. A common reporting framework could help distinguish an effect associated with the space environment from a change introduced during storage or transport. The subgroup has announced these areas of work; it has not published a completed set of new requirements in the announcement.
The scientific rationale for some of this work is already established. In microgravity, particles settle differently and buoyancy-driven fluid movement is reduced. These changes can affect crystallization and biological processing. They also make terrestrial assumptions about liquid behavior less reliable. An experiment’s records need to describe the conditions actually experienced by its materials, rather than using its location in space as a complete explanation of the result.
Pharmaceutical research illustrates the distinction between learning from space and manufacturing products there. New Space Economy’s discussion of commercial space pharmaceuticals separates drug discovery, product development, and orbital production. Each can use similar transport and laboratory infrastructure, but the intended output differs. A mission may deliver knowledge that improves a process on Earth, or it may return material intended for further development or production.
Independent reporting identifies the operational relevance. In Reuters’ September 17 report, pharmaceutical and space executives described efforts to make orbital manufacturing reliable and affordable as the International Space Station approaches retirement. The report highlighted logistics and regulatory coordination alongside scientific work. Shared payload practices address part of that coordination problem by giving participants a common basis for specifying and recording the work.
Standards can be particularly useful at organizational boundaries. The laboratory preparing a sample, the company integrating its payload, the flight operator, and the laboratory examining returned material may have different procedures. A documented interface specifies what each party must receive, preserve, and pass onward. Applied consistently, that approach can reduce repeated negotiation over basic records and make responsibilities easier to audit.
The distinction between voluntary standards and pharmaceutical regulation remains specific and important. F47.06 is developing voluntary consensus standards. Participation by government scientists brings relevant expertise into that process, but the announcement is not a drug approval or a new binding manufacturing rule. A developer must still meet the regulatory requirements applicable to its product and intended market.
The FDA’s explanation of current good manufacturing practice describes quality as a matter of process design, monitoring, and control. It includes suitable raw materials, written procedures, investigation of deviations, and reliable testing. The agency also explains why testing a small sample of a finished batch cannot establish everything about how the entire batch was made. For space production, this makes records collected throughout the mission commercially relevant, rather than simply supporting documentation.
International policy is developing alongside these technical efforts. On March 5, 2026, the UK Space Agency and partner regulators announced a space-manufactured medicines pathway. The package includes guidance, case studies, a regulatory sandbox, and supply-chain engagement. It addresses how developers work with public authorities. ASTM’s initiative has a different function: developing shared technical practices that participants can use when preparing and evaluating payload operations.
The two approaches are complementary in purpose. Regulatory coordination clarifies the authorities and evidence involved in bringing a product to market. Technical standards can organize how some of that evidence is generated and exchanged. Neither requires every experiment to use identical hardware. The practical objective is a record sufficiently clear for another qualified organization to understand the process and assess its results.
The next substantive outputs to watch are proposed standards, their defined scope, and the methods they specify for documenting conditions and evaluating returned materials. The formation announcement supplies no publication deadline for those documents. Its immediate contribution is an organized forum bringing laboratory, manufacturing, regulatory, and flight expertise together. If that work produces usable common practices, customers will have a more consistent basis for commissioning experiments, comparing results, and developing repeatable space-based processes.
Useful Books Available on Amazon
